Hydroxyzine Pamoate
27 NDCs across 8 manufacturers|27 Generic,0 Brand
Hydroxyzine Pamoate is used to treat anxiety disorders, nausea, pruritus, substance withdrawal syndrome and vomiting, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved before 1982, and the first generic was approved Jan 1, 1982. FDA's Orange Book lists 8 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $19 million on Hydroxyzine Pamoate across 1.6 million claims for 432,000 beneficiaries.
Hydroxyzine Pamoate is available as 27 NDCs from 8 manufacturers (27 generic, 0 brand), with NADAC prices from $0.06 to $0.43 per EA — the most expensive product costs about 6.7× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
27
27G / 0B
Manufacturers
8
competing in market
Price Spread
$0.06 – $0.43
per EA
7d Activity
avg +0.5% WoW · of 27 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Sandoz Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Antihistamine class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
8 manufacturers producing HYDROXYZINE PAMOATE(2 pricing outliers)
Frequently Asked Questions
What is Hydroxyzine Pamoate used to treat?
Hydroxyzine Pamoate is used to treat anxiety disorders, nausea, pruritus, substance withdrawal syndrome and vomiting, per the National Library of Medicine's MED-RT classification.
When did Hydroxyzine Pamoate become available as a generic?
FDA approved the first generic Hydroxyzine Pamoate (ANDA) on Jan 1, 1982. The Orange Book currently lists 8 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Hydroxyzine Pamoate?
In 2024, Medicare Part D spent $19 million on Hydroxyzine Pamoate across 1.6 million claims for 432,000 beneficiaries.
How many Hydroxyzine Pamoate products are on the market?
The Hydroxyzine Pamoate drug market contains 27 NDCs from 8 manufacturers — 27 generic and 0 brand products.
What is the price range for Hydroxyzine Pamoate?
NADAC reference prices for Hydroxyzine Pamoate range from $0.0636 to $0.4261 per EA — the most expensive product costs about 6.7× the cheapest.
Which manufacturers make Hydroxyzine Pamoate?
8 manufacturers list Hydroxyzine Pamoate in NADAC. Ranked by number of NDCs, the largest are Sandoz Inc. (6), Teva Pharmaceuticals USA Inc. (5), Heritage Pharmaceuticals Inc. (4), Amneal Pharmaceuticals of New York LLC (4), American Health Packaging (3).
How has the price of Hydroxyzine Pamoate changed recently?
Over the past 7 days, 12 Hydroxyzine Pamoate NDCs rose and 13 fell, with a market-wide average change of +0.5%.